CAMBRIDGE, Mass., Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST.
The 42nd Annual J.P. Morgan Healthcare Conference will take place January 8 – 11, 2024, in San Francisco, CA.
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.34 |
| Daily Change: | 0.01 0.75 |
| Daily Volume: | 2,451,130 |
| Market Cap: | US$280.560M |
March 14, 2024 January 30, 2024 January 09, 2024 November 20, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
